Compare iShares MSCI Canada (TSX) (EWC) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Zimmer Biomet Holdings Inc — how do they compare? iShares MSCI Canada (TSX) trades at $59.59, while Zimmer Biomet Holdings Inc trades at $92.72 (market cap $17.44B). The key difference: Zimmer Biomet Holdings Inc pays a 1.07% dividend while iShares MSCI Canada (TSX) pays none, and iShares MSCI Canada (TSX) is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| EWC | ZBH | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $59.49 | $107.71 |
52-Week Low | $45.86 | $79.58 |
Market Cap | — | $17.44B |
Enterprise Value | — | $24.49B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC trades at $59.38, up 0.34% today, with a bullish technical signal from moving averages but overbought RSI readings. The stock shows strong momentum near key resistance at $60, supported by positive Canadian economic news including trade surpluses and nuclear energy expansion plans. A dividend of $0.28 is scheduled for June 2026, adding income appeal.
Outlook remains positive due to Canada's economic recovery and commodity strength, though risks include US trade policy uncertainty and high RSI levels suggesting near-term consolidation. Institutional sentiment is bullish, with technical support at $59 providing a floor for potential gains.
Zimmer Biomet (ZBH) trades at $91.03, down 3.24% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows consistent earnings beats in recent quarters, with Q2 2026 results pending. Revenue growth has climbed from $6.9B in 2022 to $8.2B in 2025, though net income margin dipped to 8.56%. Recent corporate developments include a $140M acquisition and expansion in India, supporting long-term growth initiatives.
The outlook remains cautiously optimistic with a consensus price target of $97.67, implying 7% upside. Key opportunities include operational efficiency and market share gains, while risks involve debt levels rising to 32.57% of assets and competitive pressures in medical technology. Earnings on August 5 will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
